Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The biotech hit upon the upbeat interpretation by separating out the results from patients who suffered the trauma within the past nine years.
The appointment ends Zelenkofske’s brief time as chief medical officer of uniQure, the company he joined last summer from AstraZeneca.
A federal appeals court threw out a tax ruling favoring Medtronic, reigniting a long dispute with the IRS over nearly $1.36 billion in back taxes.
The FDA cleared SPR Therapeutics’ single- and dual-lead nerve stimulation devices as non-opioid alternatives for acute and chronic pain relief.
Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China.
Kyowa Hakko Kirin has posted a look at proof-of-concept data on adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease patients.
The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams.
Galera's synthetic enzyme GC4419, appears to stave off severe oral mucositis, a side effect of cancer treatment.
Tandem Diabetes Care launched a new predictive feature for automatically pausing insulin delivery as a free update for its CGM-enabled insulin pumps.
Gene-silencing specialist Sirnaomics has been cleared to start trials of its STP705 drug in bile duct cancer, its first oncology indication.